The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies.
about
Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study.Reduced miR-125a levels associated with poor survival of patients with hepatocellular cancer.NEAT1_2-SFPQ axis mediates cisplatin resistance in liver cancer cells in vitroIntra-Arterial TheraSphere Yttrium-90 Glass Microspheres in the Treatment of Patients With Unresectable Hepatocellular Carcinoma: Protocol for the STOP-HCC Phase 3 Randomized Controlled TrialEfficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma
P2860
The best strategy for HCC patients at each BCLC stage: a network meta-analysis of observational studies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
The best strategy for HCC pati ...... ysis of observational studies.
@ast
The best strategy for HCC pati ...... ysis of observational studies.
@en
type
label
The best strategy for HCC pati ...... ysis of observational studies.
@ast
The best strategy for HCC pati ...... ysis of observational studies.
@en
prefLabel
The best strategy for HCC pati ...... ysis of observational studies.
@ast
The best strategy for HCC pati ...... ysis of observational studies.
@en
P2093
P2860
P31
P356
P1433
P1476
The best strategy for HCC pati ...... ysis of observational studies.
@en
P2093
P2860
P304
20418-20427
P356
10.18632/ONCOTARGET.14668
P407
P5008
P577
2017-01-15T00:00:00Z
2017-03-21T00:00:00Z